the highest quartile of serum enterolactone was associated with a significantly reduced risk of death only for estrogen receptor-negative tumors (hr, 0.27; 95% ci, 0.08 to 0.87) but not for estrogen receptor-positive tumors (hr, 0.91; 95% ci, 0.45 to 1.84: p for heterogeneity = .09).